Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Aytu BioPharma's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $30.78 Mil. Aytu BioPharma's Total Assets for the quarter that ended in Mar. 2024 was $128.86 Mil.
Therefore, Aytu BioPharma's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was 0.24.
The historical rank and industry rank for Aytu BioPharma's Equity-to-Asset or its related term are showing as below:
LTS:0A8M'
s Equity-to-Asset Range Over the Past 10 Years
Min: -7.5 Med: 0.39 Max: 0.86
Current: 0.24
During the past 13 years, the highest Equity to Asset Ratio of Aytu BioPharma was 0.86. The lowest was -7.50. And the median was 0.39.
LTS:0A8M's Equity-to-Asset is ranked worse than 82.23% of 1086
companies
in the Drug Manufacturers industry
Industry Median: 0.58
vs LTS:0A8M: 0.24
Aytu BioPharma Equity-to-Asset Historical Data
The historical data trend for Aytu BioPharma's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Aytu BioPharma's Equity-to-Asset
For the Drug Manufacturers - Specialty & Generic subindustry, Aytu BioPharma's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aytu BioPharma's Equity-to-Asset Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aytu BioPharma's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Aytu BioPharma's Equity-to-Asset falls into.
Aytu BioPharma Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Aytu BioPharma's Equity to Asset Ratio for the fiscal year that ended in Jun. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Aytu BioPharma Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Aytu BioPharma's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complimentary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. AR101/enzastaurin has received Orphan Drug designation from the FDA. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which it generates maximum revenue from the Rx segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LTS:0A8M has been successfully added to your 